Literature DB >> 21848956

Update of prevalence of self-reported allergic rhinitis and chronic nasal symptoms among adults in Sweden.

Jonas Eriksson1, Linda Ekerljung, Eva Rönmark, Barbro Dahlén, Staffan Ahlstedt, Sven-Erik Dahlén, Bo Lundbäck.   

Abstract

BACKGROUND: Allergic rhinitis (AR) is the most common immunologic disease, and it renders a considerable burden on both sufferers and society. The prevalence of AR has been increasing worldwide over the past century. The aim of this study was to assess the present prevalence, risk factor patterns and comorbidity of self-reported AR and chronic nasal symptoms in different age groups in Stockholm, Sweden.
METHODS: A postal questionnaire was sent on two occasions, in 2006 to a population aged 30-80 years, randomly selected 10 years previously, and in 2007 to a randomly selected sample of subjects aged 20-69 years. The response rates were 83% and 68%, respectively, and in total, 9792 subjects participated. The questionnaire included questions on self-reported AR, asthma, respiratory and nasal symptoms and possible determinants.
RESULTS: The prevalence of self-reported AR was 28.0% (men 26.6%, women 29.1%, P < 0.01) similar to 10 years previously and 33.6% in ages 30-40 years. Allergic heredity [odds ratio (OR) 4.76, confidence interval (CI) 95% 4.25-5.33], physician-diagnosed asthma (OR 5.29, CI 95% 4.49-6.24) and occupational exposure to dust, gases and fumes (OR 1.49, CI 95% 1.30-1.72) were determinants for AR. Prevalence of chronic nasal congestion was 16.1% and of chronic rhinorrhea 14.1%.
CONCLUSIONS: As a basis for understanding the disease, as well as in planning and prioritizing health-care resources, the study provides information about the current prevalence and determinants of self-reported AR and chronic nasal symptoms. Further, comparing with previous studies, the present study suggests that a plateau in the prevalence of AR may have been reached in Sweden.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21848956     DOI: 10.1111/j.1752-699X.2011.00269.x

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  16 in total

1.  International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.

Authors:  Sarah K Wise; Sandra Y Lin; Elina Toskala; Richard R Orlandi; Cezmi A Akdis; Jeremiah A Alt; Antoine Azar; Fuad M Baroody; Claus Bachert; G Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M DelGaudio; Charles S Ebert; Jean Anderson Eloy; Carrie E Flanagan; Wytske J Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G Hamilton; Hans Jürgen Hoffman; Jens M Hohlfeld; Steven M Houser; Peter H Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N Khalid; Maritta Kilpeläinen; Todd T Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M Laury; Stella E Lee; Joshua M Levy; Amber U Luong; Bradley F Marple; Edward D McCoul; K Christopher McMains; Erik Melén; James W Mims; Gianna Moscato; Joaquim Mullol; Harold S Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J Schlosser; Russell A Settipane; Hemant P Sharma; Aziz Sheikh; Timothy L Smith; Pongsakorn Tantilipikorn; Jody R Tversky; Maria C Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek
Journal:  Int Forum Allergy Rhinol       Date:  2018-02       Impact factor: 3.858

2.  Rhinitis, asthma and respiratory infections among adults in relation to the home environment in multi-family buildings in Sweden.

Authors:  Juan Wang; Karin Engvall; Greta Smedje; Dan Norbäck
Journal:  PLoS One       Date:  2014-08-19       Impact factor: 3.240

3.  Asthma, allergy and eczema among adults in multifamily houses in Stockholm (3-HE study)--associations with building characteristics, home environment and energy use for heating.

Authors:  Dan Norbäck; Erik Lampa; Karin Engvall
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

4.  Exosomes in the nose induce immune cell trafficking and harbour an altered protein cargo in chronic airway inflammation.

Authors:  Cecilia Lässer; Serena E O'Neil; Ganesh V Shelke; Carina Sihlbom; Sara F Hansson; Yong Song Gho; Bo Lundbäck; Jan Lötvall
Journal:  J Transl Med       Date:  2016-06-20       Impact factor: 5.531

5.  Smoking, environmental tobacco smoke and occupational irritants increase the risk of chronic rhinitis.

Authors:  Hanna Hisinger-Mölkänen; Päivi Piirilä; Tari Haahtela; Anssi Sovijärvi; Paula Pallasaho
Journal:  World Allergy Organ J       Date:  2018-03-14       Impact factor: 4.084

6.  Job titles classified into socioeconomic and occupational groups identify subjects with increased risk for respiratory symptoms independent of occupational exposure to vapour, gas, dust, or fumes.

Authors:  Christian Schyllert; Martin Andersson; Linnea Hedman; Magnus Ekström; Helena Backman; Anne Lindberg; Eva Rönmark
Journal:  Eur Clin Respir J       Date:  2018-05-15

Review 7.  Epidemiology and natural history of atopic diseases.

Authors:  Simon F Thomsen
Journal:  Eur Clin Respir J       Date:  2015-03-24

8.  Prevalence and sensitization of atopic allergy and coeliac disease in the Northern Sweden Population Health Study.

Authors:  Stefan Enroth; Ingrid Dahlbom; Tony Hansson; Åsa Johansson; Ulf Gyllensten
Journal:  Int J Circumpolar Health       Date:  2013-08-05       Impact factor: 1.228

9.  Rhinitis symptoms and asthma among parents of preschool children in relation to the home environment in Chongqing, China.

Authors:  Juan Wang; Baizhan Li; Wei Yu; Qin Yang; Han Wang; Duchai Huang; Jan Sundell; Dan Norbäck
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

10.  An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011.

Authors:  X D Wang; M Zheng; H F Lou; C S Wang; Y Zhang; M Y Bo; S Q Ge; N Zhang; L Zhang; C Bachert
Journal:  Allergy       Date:  2016-04-13       Impact factor: 13.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.